FMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fresenius Medical Care AG (FMS) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company's financial performance has shown solid growth in revenue, net income, and EPS in the latest quarter, the lack of positive trading signals, neutral insider and hedge fund activity, and a mixed analyst sentiment suggest that it would be prudent to hold off on investing in this stock for now. Additionally, the technical indicators do not provide a strong entry signal, and the options data does not indicate a bullish sentiment.
The MACD histogram is positive at 0.234, indicating a bullish trend, but it is contracting, suggesting weakening momentum. The RSI is at 76.103, which is in the neutral zone, not indicating overbought or oversold conditions. Moving averages are converging, showing no clear trend direction. Key resistance levels are at 24.383 and 24.89, while support levels are at 22.74 and 22.233.
The company's financial performance in Q3 2025 showed strong growth, with revenue up 9.17% YoY, net income up 37.23% YoY, EPS up 37.50% YoY, and gross margin up 5.61% YoY.
Analyst sentiment is mixed to negative, with multiple firms lowering price targets and highlighting headwinds such as sluggish treatment volume growth, potential regulatory changes, and incremental training costs. No recent news or significant trading trends from insiders or hedge funds. Congress trading data is also absent.
In Q3 2025, Fresenius Medical Care AG reported revenue of $5.71 billion, up 9.17% YoY. Net income increased to $321.19 million, up 37.23% YoY. EPS rose to 1.1, up 37.50% YoY. Gross margin improved to 25.43%, up 5.61% YoY. These figures indicate strong financial growth in the latest quarter.
Analyst sentiment is mixed to negative. Goldman Sachs downgraded the stock to Neutral from Buy, citing headwinds in fiscal 2026. Morgan Stanley and Citi maintain Underweight and Neutral ratings, respectively, with lowered price targets. Truist raised its price target slightly but maintains a Hold rating. Overall, analysts highlight challenges such as sluggish treatment volume growth and regulatory uncertainties.
